15 years of research and development (R&D) activities conducted by a mounting plethora of product development partnerships (PDPs) have determined a dense pipeline of candidates for products aimed at tackling diseases that particularly affect people in poor countries.

This recent development in terms of medical innovation is to be welcome in many ways. However, time has come to closely analyze the new North-driven and North-focused architecture for R&D that has emerged out of this trend, with its controversial implications.

Meanwhile, the springing up of an alternative research agenda – steered by public leadership in countries where needs are – is yet to be seen, despite the availability of new negotiated instruments like the WHO “Global Strategy on Public health, innovation and Intellectual Property".

An analysis by Janis Lazdins, former researcher at TDR


Your comments

Reply to this article

Who are you?
Enter your comment here

Suivre les commentaires : RSS 2.0 | Atom

HOME | ABOUT HIP | OUR WORK | KEY DOCUMENTS | DIALOGUE WITH HIP | CONTACT US | LINKS
© Copyright 2018 - Creation: Internet Diffusion Photos: Claire-Lise Chaignat, Martine Berger